Literature DB >> 28377491

One evidence base; three stories: do opioids relieve chronic breathlessness?

Magnus Ekström1, Sabrina Bajwah2, J Martin Bland3, David C Currow4, Jamilla Hussain5, Miriam J Johnson5.   

Abstract

The efficacy of low-dose systemic opioids for chronic breathlessness was questioned by the recent Cochrane review by Barnes et al We examined the reasons for this conflicting finding and re-evaluated the efficacy of systemic opioids. Compared with previous meta-analyses, Barnes et al reported a smaller effect and lower precision, but did not account for matched data of crossover trials (11/12 included trials) and added a risk-of-bias criterion (sample size). When re-analysed to account for crossover data, opioids decreased breathlessness (standardised mean differences -0.32; -0.18 to -0.47; I2=44.8%) representing a clinically meaningful reduction of 0.8 points (0-10 numerical rating scale), consistent across meta-analyses. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  COPD Pharmacology; Palliative Care; Perception of Asthma/Breathlessness

Mesh:

Substances:

Year:  2017        PMID: 28377491     DOI: 10.1136/thoraxjnl-2016-209868

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  20 in total

Review 1.  Updates in palliative care - recent advancements in the pharmacological management of symptoms.

Authors:  Angela Star; Jason W Boland
Journal:  Clin Med (Lond)       Date:  2018-02       Impact factor: 2.659

2.  Palliative drug treatments for breathlessness in cystic fibrosis.

Authors:  Nishant Jaiswal; Meenu Singh; Amit Agarwal; Anil Chauhan; Nikita Jaiswal
Journal:  Cochrane Database Syst Rev       Date:  2020-04-28

3.  Fentanyl treatment for end-of-life dyspnoea relief in advanced cancer patients.

Authors:  Miguel Angel Benítez-Rosario; Inmaculada Rosa-González; Enrique González-Dávila; Emilio Sanz
Journal:  Support Care Cancer       Date:  2018-06-18       Impact factor: 3.603

Review 4.  Palliative drug treatments for breathlessness in cystic fibrosis.

Authors:  Nishant Jaiswal; Meenu Singh; Amit Agarwal; Kiran K Thumburu
Journal:  Cochrane Database Syst Rev       Date:  2017-08-10

5.  A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion And Morphine Sulfate (BEAMS) study protocol.

Authors:  David Currow; Gareth John Watts; Miriam Johnson; Christine F McDonald; John O Miners; Andrew A Somogyi; Linda Denehy; Nicola McCaffrey; Danny J Eckert; Philip McCloud; Sandra Louw; Lawrence Lam; Aine Greene; Belinda Fazekas; Katherine C Clark; Kwun Fong; Meera R Agar; Rohit Joshi; Sharon Kilbreath; Diana Ferreira; Magnus Ekström
Journal:  BMJ Open       Date:  2017-07-17       Impact factor: 2.692

6.  Fooling the brain to alleviate dyspnoea.

Authors:  Capucine Morélot-Panzini
Journal:  Eur Respir J       Date:  2017-08-17       Impact factor: 16.671

Review 7.  Breathlessness services as a new model of support for patients with respiratory disease.

Authors:  Claudia Bausewein; Michaela Schunk; Philipp Schumacher; Julika Dittmer; Anna Bolzani; Sara Booth
Journal:  Chron Respir Dis       Date:  2017-07-18       Impact factor: 2.444

8.  Management of the COPD Patient with Comorbidities: An Experts Recommendation Document.

Authors:  Jesús Recio Iglesias; Jesús Díez-Manglano; Francisco López García; José Antonio Díaz Peromingo; Pere Almagro; José Manuel Varela Aguilar
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-05-07

9.  Holistic services for people with advanced disease and chronic breathlessness: a systematic review and meta-analysis.

Authors:  Lisa Jane Brighton; Sophie Miller; Morag Farquhar; Sara Booth; Deokhee Yi; Wei Gao; Sabrina Bajwah; William D-C Man; Irene J Higginson; Matthew Maddocks
Journal:  Thorax       Date:  2018-11-29       Impact factor: 9.139

10.  Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility).

Authors:  Irene J Higginson; Andrew Wilcock; Miriam J Johnson; Sabrina Bajwah; Natasha Lovell; Deokhee Yi; Simon P Hart; Vincent Crosby; Heather Poad; David Currow; Emma Best; Sarah Brown
Journal:  Thorax       Date:  2020-01-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.